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ABSTRACT 
Metabolomics is complementary to genomics, transcriptomics and proteomics; 
however, it has the capacity to reflect the activities of the organism at a functional 
level. Metabolomics can therefore be used as a diagnostic tool by identifying the up- or 
down-regulation of metabolites in the cell, tissue, plasma, serum or urine. Specifically, 
these are, but are not limited to, identifying biomarkers of disease, monitoring drug 
treatments, and monitoring surgical procedures such as organ transplant. Autosomal 
recessive polycystic kidney disease (ARPKD) makes up 5-8% of patients requiring 
kidney dialysis and/or transplantation and of these, an estimated 50% of patients 
progress to end-stage renal disease (ESRD) by the age of 10 years, resulting in renal 
and liver-related morbidity and mortality. The purpose of this research was to utilise 
the Lewis Polycystic Kidney (LPK) rat to investigate the ARPKD phenotype using 
metabolomics. Spot urine samples were collected from 7 male Lewis; 8 male LPK; and 
6 female LPK rats aged 5 weeks. Metabolites were extracted from urine and 
derivatised for GC/MS analysis. The peak area of target components was normalised to 
the internal standard ribitol and then to creatinine. Principal component analysis (PCA) 
was used to visualise sample grouping and the loadings plot of the PCA was used to 
determine key metabolites attributed to the variance between sample groups. a-
ketoglutarate, uric acid and allantoin were proposed as potential biomarkers for 
ARPKD in the 5-week old male LPK rat. The findings of this study, particularly the 
development of a GC/MS method to analyse Lewis and LPK rat urine, demonstrate the 
potential of metabolomics to further investigate ARPKD. 
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1.1 Metabolomics 
CHAPTER ONE 
INTRODUCTION 
The relatively new field of metabolomics is defined as the study of the 
metabolome (i.e. all metabolites in the cell, tissue and/or biofluid(s)) [1-5]. 
Metabolomics is complementary to genomics, transcriptomics and proteomics, 
however, it has the capacity to reflect the activities of the organism at a functional 
level [6, 7]. Metabolites are products of enzyme-catalysed reactions [8] and, although 
it is known that changes in the quantities of enzymes may have little effect on 
metabolic processes, significant effects can be seen in the concentration of individual 
metabolites [6]. As this suggests, metabolites are integral to the function and survival 
of the cell [3], most commonly participating in the production and release of energy or 
as a precursor to such transfer processes [3]. Metabolomics can therefore be used as a 
diagnostic tool by identifying the up- or down-regulation of metabolites in the cell, 
tissue, plasma, serum or urine [9]. Specifically, these are, but are not limited to, 
identifying biomarkers of disease [9], monitoring drug treatments [9, 10] and 
monitoring surgical procedures such as organ transplant [4, 5]. 
Also termed metabonomics or metabolic profiling [4], the advent of 
metabolomics has been in light of recent technological advancements in the 
separation and identification of small, low molecular weight molecules [4, 11], and also 
in software for processing the resultant large quantities of data [5]. As the properties 
of metabolites such as polarity, volatility and solubility vary so greatly, metabolomic 
analysis requires the use of several complimentary analytical techniques [2]. The most 
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common approaches in metabolomics have been capillary electrophoresis [12, 13], gas 
chromatography mass spectrometry {GC/MS) [2, 8, 14, 15], liquid chromatography 
mass spectrometry {LC/MS) [2, 14, 16] and proton nuclear magnetic resonance 
spectroscopy {1H NMR) [1, 14, 16]. GC/MS is the method of choice for the screening of 
non-targeted metabolites due to its ability to resolve hundreds of metabolites in a 
single injection [2]. Coupled with the sensitivity and ability of MS to provide structural 
information, the detection, separation and identification of metabolites is now 
possible [2]. 
Gas chromatography has been widely used in metabolomics studies [3, 6, 8-10, 
15, 17-20]. GC consists of an injection system, mobile phase, the column (stationary 
phase) and a detector [3, 21]. A sample (gas or liquid) is injected through a septum into 
an injection port and is rapidly volatilised [21]. Analytes are swept onto the column 
and are separated according to volatility and diffusion between the mobile and 
stationary phases [21]. Separated analytes then flow through to the detector which 
records a response [21]. 
The mobile phase in gas chromatography is known as the carrier gas, and is 
typically helium, nitrogen, or hydrogen [21]. The carrier gas used is largely dependent 
upon the detector employed however, where the detector is not an issue, significant 
differences can be found in separation efficiency and the speed of GC analysis by 
selecting the appropriate carrier gas [21]. For example, hydrogen will yield the fastest 
separation time followed by helium and then nitrogen [21]. In metabolomics, however, 
mass spectrometers are generally used as the method of detection in gas 
chromatography [3]. For this reason, helium is employed as the carrier gas. Helium and 
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hydrogen show superior resolution as analytes diffuse between phases more rapidly 
through these carrier gases than through nitrogen [21]. Hydrogen may protonate 
analytes and can potentially interfere with the MS vacuum pump [21]. For these 
reasons, helium is the obvious choice of carrier gas in metabolomics separations using 
GC/MS. 
The method of injection in gas chromatography is critical as it is at this point 
that the sample is transferred to the mobile phase and focused at the beginning of the 
column [3]. Villas-Boas eta/. [3] have identified this as one of the major causes of error 
in gas chromatography, being particularly attributed to slow and/or incomplete 
volatilisation of analytes. To prevent this, metabolites must be converted to a volatile 
form. This process is known as derivatisation and is a considerable limitation of GC/MS 
due to its arduous and time consuming nature. Splitless injections are widely used in 
non-targeted metabolic profiling [9, 15, 17, 19] as these are typically classed as trace 
analyses. A split injection is commonly used to achieve baseline separation when the 
concentration of a sample is known to be high or is unknown. It is a preventative 
measure to minimise overloading the column and this is especially the case when using 
capillary columns as micrograms of analyte can cause overloading [21]. 
There is a wealth of column technology available to GC practitioners. 
Essentially, there are two types of GC columns; packed and open. Open tubular 
columns are the most commonly used in GC analyses. They are long and narrow in 
structure and are made of polyimide-coated fused silica. Open tubular columns offer 
greater sensitivity, higher resolution, and shorter analysis time [21]. These features 
make the application of open tubular columns ideal for research in the field of 
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metabolomics. The common coupling of GC to MS requires Low bleed columns. These 
are typically non-polar capillary columns which amplify the need for derivatisation (i.e. 
to reduce the polarity of metabolites) for successful high resolution chromatography. 
Mass spectrometry is commonly employed as the method of detection in 
metabolomics research [7, 11, 22]. In fact, Villas-Boas eta/. [3] have identified mass 
spectrometry as the driving force behind the recent emergence of metabolomics. To 
briefly describe MS, molecules are ionised by either electron or chemical ionisation 
processes, are accelerated by an electric field and then separated according to their 
mass-to-charge (m/z) ratio [21]. There are many different types of mass spectrometers 
however, for the purpose of this research, only two will be discussed here. These are 
the linear quadrupole mass spectrometer and the ion trap quadrupole mass 
spectrometer. 
In linear quadrupole mass spectrometry, four rods are assembled parallel to 
one another. A constant voltage and a radio frequency oscillating voltage are applied 
to the rods to stabilise the ion trajectory for a given m/z species as it migrates to the 
detector. This can, however, result in the loss of sensitivity for destabilised ions. In ion 
trap quadrupole mass spectrometry, ions are trapped by a ring electrode and two end 
caps. ion trajectories are destabilised in order to reach the detector in a uniform 
stream which results in superior sensitivity in comparison to the linear quadrupole 
mass spectrometer. 
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1.2 Polycystic Kidney Disease 
Polycystic kidney .diseases (PKD) are inherited diseases characterised by renal 
tubular defects [23]. Advances in molecular genetics have allowed the characterisation 
of the three PKD genes; PKD1, PKD2 and PKHD1 [24]. By combining these findings with 
the descriptive data obtained from previous mapping of genetic cystic diseases, the 
molecular and cellular mechanisms of the diseases can now be systematically and 
thoroughly investigated [24]. Two modes of inheritance have been characterised for 
the polycystic kidney diseases. The first and most common is autosomal dominant 
polycystic kidney disease (ADPKD) which is caused by mutations in the PKD1 (polycystic 
kidney disease 1) or PKD2 (polycystic kidney disease 2) genes [25] and results in focal 
cyst development [23]. The second is autosomal recessive polycystic kidney disease 
(ARPKD) which is caused by mutations in the PKHD1 (polycystic kidney and hepatic 
disease 1) gene [25], commonly resulting in tubule dilation [23, 26, 27]. 
Autosomal recessive polycystic kidney disease (ARPKD), far less common than 
ADPKD, has an incidence of 1 in 20 000 [24, 28] which makes up 5-8% of patients 
requiring kidney dialysis and/or transplantation [24]. Unlike ADPKD, ARPKD is most 
commonly evident in utero or at birth but has also been characterised in later 
childhood and in patients over 20 years of age [24, 28]. An estimated 50% of patients 
progress to end-stage renal disease (ESRD) by the age of 10 years, resulting in renal 
and liver-related morbidity and mortality despite recent advancements in neonatal 
and intensive care [24]. 
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Symptoms of ARPKD include fusiform dilation of renal collecting tubules or 
ducts and/or focal cyst development [23] as well as dysgenesis of the hepatic portal 
triad (congenital hepatic fibrosis) [24]. As this suggests, ARPKD is a member of a group 
of congenital hepatorenal fibrocystic diseases [29] characterised by both renal and 
hepatic involvement [24]. Dilation of the collecting tubules can be evident in 10-90% of 
tubules, accounting for the vast variability in renal dysfunction and kidney 
enlargement [24]. The manifestation of liver disease consisting of biliary dysgenesis 
and congenital hepatic fibrosis varies from patient to patient according to age at 
presentation, however liver involvement is a symptom of all ARPKD patients [24]. The 
most common cause of morbidity and mortality in new born patients is pulmonary 
hypoplasia, often resulting in respiratory insufficiency [24]. However, for patients who 
survive the neonatal and perinatal periods, ARPKD can present with systemic 
hypertension, renal failure, portal hypertension, and fibrosis of both the kidneys and 
liver also resulting in morbidity and mortality [24]. 
The different phenotypes of the disease were originally thought to be caused 
by different mutant genes [24]. Since then, all phenotypes of ARPKD have been 
attributed to a mutation at a single locus; the PKHD1 (polycystic kidney and hepatic 
disease 1) gene, which is located on chromosome 6p21.1-p12 [24, 30]. PKHD1 is a 
large gene, spanning approximately 470 kb of genomic DNA and producing eDNA of 9-
16 kb [24, 28]. A minimum of 86 exons is assembled into a variety of alternatively 
spliced transcripts [24, 28]. The longest continuous open reading frame {ORF) is 
predicted to yield a 4074-amino acid protein called fibrocystin or polyductin which is 
believed to be involved in collecting tubule and biliary duct formation, however the 
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exact function is unknown [24, 31]. It is anticipated that multiple variations of the 
protein are produced by the complicated transcription of the PKHD1 gene [24]. 
Recent research in ARPKD has centred on determining the localisation and 
function of the PKHD1 protein fibrocystin/polyductin [23, 27, 28, 32, 33]; the 
molecular/cellular pathogenesis and cystogenesis of the disease [24, 28]; diagnostic 
applications [34]; and therapeutic interventions for patients suffering from ARPKD [24, 
28]. This research has encompassed the use of many laboratory animal models of 
ARPKD including the Pkhd1 del2/del2 mice [27L the polycystic kidney {PCK) rat [33] and 
the lewis polycystic kidney {LPK) rat [35]. There is little evidence to show that 
metabolomics has been identified as a tool to investigate ARPKD. Therefore, the 
purpose of this research is to utilise the LPK rat model to investigate the ARPKD 
phenotype using a metabolomics approach. 
1.3 Research Questions 
1. Is it possible to accurately and reliably detect metabolites in Lew/LPK 
rat urine using GC/MS? 
2. Can this method be optimised to see a greater profile of metabolites at 
lower detection limits? 
3. Are there any significant differences between the metabolic profiles of 
Lewis and LPK rats? 
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1.4 Definitions of Selected Terms 
ADPKD Autosomal dominant polycystic kidney disease 
AEC Animal Ethics Committee 
AN OVA Analysis of variance 
ARC Animal Resources Centre 
ARPKD Autosomal recessive polycystic kidney disease 
ESRD End stage renal disease 
eV Electron volt 
GC Gas chromatography 
GC/MS Gas chromatography mass spectrometry 
IS Internal standard 
LC Liquid chromatography 
LC/MS Liquid chromatography mass spectrometry 
LEW Lewis 
LPK Lewis polycystic kidney 
m/z Mass-to-charge ratio 
M Moles per litre 
mg Milligram 
mL Millilitre 
MeOH Methanol 
MS Mass spectrometry 
MSTFA N-methyi-N-(trimethylsilyl)trifluroacetamide 
ng Nanogram 
ng.~L-1 Nanograms per microlitre 
NIST National Institute of Standards and Technology 
8 
1H NMR 
p 
PC1 
PC2 
PCA 
PCK 
PKD 
PKD1 
PKD2 
PKHD1 
u 
U.~-tL- 1 
1-lg 
Ill 
Proton nuclear magnetic resonance 
Probability. 
Principal component 1 
Principal component 2 
Principal component analysis 
Polycystic kidney 
Polycystic kidney disease 
Polycystic kidney disease 1 gene 
Polycystic kidney disease 2 gene 
Polycystic kidney and hepatic disease 1 gene 
Unit 
Units per microlitre 
microgram 
micro litre 
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2.1 Chemicals 
CHAPTER TWO 
METHODS 
D-mannitol (>99%), ribitol (>99%), methoxyamine-HCI (98%), N-methyi-N-
(trimethylsilyl)trifluroacetamide (MSTFA) (>98.S%), pyridine (>99%), n-alkanes C10, C12, 
C1s, C19, C22, C2s, C32 and C36 (>98%), type Ill jack bean urease (40100 U.g-1) and 
creatinine (>98%) were all purchased from Sigma Aldrich; Australia. n-hexane (>9S%) 
and methanol (HPLC grade >99%) were purchased from LabScan; Australia. Helium 
cylinders (UHP) were purchased from BOC Gases; Australia. 
2.2 Standards 
Seven concentrations (0.01, O.OS, 0.1, 0.5, 1, S and 10 ng.jlL-1) of D-mannitol 
were prepared to calculate limit of detection (LOD) and precision of the GC/MS. A 
stock solution of D-mannitol (6.5 mg.L-1) was prepared from which 0.1, O.S, 1, S, 10 
and SO ml aliquots were taken and made up to 100 ml with milli-Q water (the stock 
was used to prepare the 10 ng.jll-1 standard). The internal standard, ribitol, was added 
to each at a desired final concentration of SO ng.jll-1. Multiple 100 Ill aliquots of each 
of the standards were dried in an Eppendorf Concentrator Plus vacuum concentrator 
and were either derivatised for GC/MS analysis or frozen at -80°C until further use. A 
similar approach was taken to add ribitol to experimental samples, however the 
desired final concentration was 1S ng.jll-1. n-alkanes were used for Kovats Index 
calculation. Individual solutions of the each of the alkanes were made up to 1 ml in 
hexane at a concentration of O.S mg.ml-1. An alkane mixture was prepared from the 
individual solutions at a concentration of 0.062S mg.ml-1 in 8 ml. 
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2.3 Laboratory Animals 
Lewis and LPK rat urine samples were purchased from the Animal Resources 
Centre (ARC), Canning Vale, Western Australia. The animals were housed together in 
cages with steam cut wheaten chaff, at ambient temperature (20-25°C}. The animals 
were fed a vegetarian diet of Standard Laboratory Rat and Mouse Cubes (Specialty 
Feeds, Glen Forrest; Western Australia) and had water available at all times. Phillips 
eta/. [35] outlines the method by which the disease was transmitted to the laboratory 
animals and also the method by which the mode of inheritance (autosomal recessive) 
was characterised. Spot urine samples (50-500 IJ.L) were collected from 3 male Lewis; 2 
female Lewis; and 5 male LPK rats aged approximately 11 weeks. These samples were 
pooled and used for method development. For experimental work, urine was collected 
from 7 male Lewis; 8 male LPK; and 6 female LPK rats aged 5 weeks. Registration as an 
animal researcher was sought and approved by Murdoch University's Animal Ethics 
Committee (AEC) and ethical approval for this study was sought and approved by Edith 
Cowan University's AEC. Approval number: Project 2144 MARTINS; Investigating Beta-
amyloid clearance in vivo 06-A9. 
2.4 Metabolite Extraction 
Urine from Lewis rats (control) was used to optimise the extraction procedure. 
Samples from 11-week old male and female rats were pooled (50 IJ.L unless otherwise 
stated) and urease (1 unit per microlitre of urine unless otherwise stated) was added. 
The samples were incubated at 37"C (30 minutes unless otherwise stated). The 
samples were then centrifuged at 4000 rpm for 10 minutes. Following this, 
-40oC methanol containing the ribitol internal standard was added to the sample. The 
calculation for the concentration of ribitol in the extraction solvent was based on 
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achieving a final ribitol concentration of 15 ng.11L-1 or 15 ng 'on column'. The samples 
were then agitated at 1200 rpm for 10 minutes and following this were centrifuged at 
4°C and 12000 rpm for 10 minutes. Aliquots {50 11L) of the sample were dried in an 
Eppendorf Concentrator Plus vacuum concentrator and frozen at -80°C until further 
use. 
2.5 Metabolite Derivatisation 
Extracted metabolites were treated with 20 11L of 20 mg.ml-1 methoxylamine-
HCI in pyridine and agitated at 1200 rpm at a temperature of 30°C in an Eppendorf 
Thermomixer Comfort {NSW, Australia) for 90 minutes. Following this, 40 11L of N-
methyi-N-{trimethylsilyl)trifluroacetamide {MSTFA) was added and the metabolites 
were incubated at 3rc for 30 minutes in the thermomixer. The metabolites were 
agitated for the first 1-2 minutes of this incubation period to mix the MSTFA. The 60 11L 
sample was then transferred to a 31 x 5 mm 0.1 ml clear GC vial insert inside an 
Alltech GC vial containing 5 11L of an alkane mix in hexane. 
2.6 Instrumentation 
2.6.1 Quadrupole GC/MS (Murdoch University) 
An Agilent 6890 series Gas Chromatograph equipped with an Agilent 5973N 
mass selective detector was used. The column employed was a Varian Factor Four 
fused silica capillary column VF SMS {30 m x ID = 0.25 mm x DF = 0.25 11m+ 10 m EZ-
Guard). The derivatised sample {1 11L) was injected splitless into the inlet at a 
temperature of 230°C. The initial column temperature was 70°C and the temperature 
ramp was set to 5.63°C.min-1 to a final temperature of 330°C. The carrier gas used was 
helium at a flow rate of 1 ml.min-1 {constant flow). The transfer line was set at 330°C 
and the ion source was set to 230°C. Ionisation was achieved with a 70 eV electron 
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beam and the mass spectrometer was set to scan ion masses in the range of 45 - 600 
m/z. 
2.6.2 lon trap GC/MS (Murdoch University) 
A Varian CP 3800 Gas Chromatograph (Australia) equipped with a Varian 1177 
split/splitless capillary injector, Varian CP 8400 autosampler (Australia) and a Varian 
Saturn 2200 GC/MS/MS ion trap mass spectrometer (Australia) was used. The column 
employed was a Varian Factor Four fused silica capillary column VF 5MS {30 m x ID = 
0.25 mm x DF = 0.25 11m + 10 m EZ-Guard). The derivatised sample (1 IlL) was injected 
splitless into the inlet at a temperature of 230°C. The initial column temperature was 
70oC and the temperature ramp was set to 5.63°C.min·1 to a final temperature of 
330°C. The carrier gas used was helium at a flow rate of 1 mL.min-1 (constant flow). 
The transfer line was set at 330°C and the ion source was set to 230°C. Ionisation was 
achieved by a 70 eV electron beam and the mass spectrometer was set to scan ion 
masses in the range of 45- 600 m/z. 
2.6.3 lon trap GC/MS (Edith Cowan University) 
A Varian Star 3400 CX gas chromatography system (Australia) equipped with a 
Varian Saturn 2000 GC/MS/MS ion trap mass spectrometer (Australia) was used. The 
column employed was a Varian Factor Four fused silica capillary column VF 5MS {30 m 
x ID = 0.25 mm x DF = 0.25 11m + 10 m EZ-Guard). The derivatised sample (1 IlL) was 
injected splitless into the inlet at a temperature of 230°C. The initial column 
temperature was 50°C and was ramped to 70oC in the first 2 minutes of the run time. 
Thereafter the temperature ramp was set to 5.60oC.min·1 for 45.35 minutes to a final 
temperature of 330°C. The carrier gas was helium at a flow rate of 1 mL.min-1 
(constant pressure). The transfer line was set at 330°C and the ion source was set to 
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230°C. Ionisation was achieved by a 70 eV electron beam and the mass spectrometer 
was set to scan ion masses in the range of 45- 600 m/z. 
2. 7 Data Analysis 
GC chromatograms and mass spectra were viewed using AnalyzerPro v2.2.0. 7 
{SpectraiWorks, UK). AnalyzerPro was used to identify all unique components (i.e. 
peaks) of the chromatogram and also to identify target components, which were 
stored in a user-generated library (Metabolomics Australia Node; Murdoch University). 
Target components were added to the library according to retention time, Kovats 
Index and deconvoluted mass spectrum (base peak). Analytes in the sample 
chromatograms were resultantly matched to these parameters. In addition to being 
compared with the user-generated library, spectra were compared with the National 
Institute of Standards and Technology {NIST) Mass Spectral library to aid in the 
identification of significant unknown metabolites. The identification generated by the 
NIST library was given a probability score {%) which was based on base peak and 
fragmentation pattern identification. AnalyzerPro was used to generate a Microsoft 
Office Excel spreadsheet of the metabolites and their peak area in each of the samples. 
This OlJtput was used to determine the precision and reproducibility of the results and 
was also used to run univariate statistical and multivariate analyses. The peak area of 
each metabolite was normalised to the internal standard, ribitol, and then to 
creatinine. 
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2.8 Statistical Analysis 
Univariate statistkal analyses were conducted using SPSS v17.0. Where there 
were two groups of data to compare, a paired samples t-test was used with a 
confidence interval of 0.95 and significance level of P=0.05. Where there were more 
than two groups of data to compare, a one-way analysis of variance (AN OVA) was used 
with Bonferroni post hoc multiple comparisons. A confidence interval of 0.95 and 
significance level of P<0.05 were adopted. Where it was appropriate to test for 
correlations in the data, particularly between the sums of the peak areas of the 
components in a sample to the peak area of the component used to normalise the 
data, a Pearson correlation was employed. In this instance a confidence interval of 
0.99 and significance level of P<0.01 were used. Multivariate principal component 
analysis (PCA) was conducted using The Unscrambler® v9.8 software package (CAMO, 
Norway). The data was log transformed using the equation x = log(x + 1). 
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CHAPTER THREE 
·RESULTS AND DISCUSSION 
3.1 Extraction Optimisation 
Urine, containing the highest number of polar metabolites in comparison to 
other biofluids, offers a rich source of metabolic information and is commonly used for 
metabolomics research [9, 10, 15, 16, 25, 36-39]. Urine was of particular interest in this 
research as the focus was on kidney disease. There is currently no agreed guideline for 
sample preparation and analysis of urine for metabolomics [40]. For this reason, it was 
necessary to undertake an extraction optimisation study to suit the operating 
conditions of the various GC/MS systems. This involved optimising urease incubation 
(concentration and incubation time), the urine volume extracted, and centrifugation 
procedures. The results and discussion of these parameter~ are detailed below. 
3.1.1 Urease incubation 
Urea is present in high concentrations in urine and has the potential to obscure 
closely eluting analytes and overload the mass spectrometer [15]. This issue is 
commonly resolved by adding urease [9, 15, 18, 19] which catalyses the hydrolysis of 
urea (Cb(NH 2h) to carbon dioxide and ammonia. Initially, urease was added to a 
200 j..lL pooled urine sample (11-week Lewis male and female) at a concentration of 
0.3 U.j..lL-1 of urine and was incubated at 3rc for 10 minutes. The sample was then 
dried and derivatised with MSTFA as previously described in section 2.3. The resulting 
chromatogram (Figure 1) shows an overloaded peak in the region of RT 16.7-19.8 
minutes which was attributed (by retention time and mass spectral analysis) to urea. 
Zhang et a/. [15] reported that 0.15 units of urease per microlitre of urine and an 
incubation period of 15 minutes was adequate to degrade urea from rat urine, 
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however the results here clearly showed the need for a greater concentration of 
urease and an extended .incubation period for the Lewis/LPK rat urine. It can also be 
seen that the intensity of some of the other analytes was 1.2 x 108, suggesting 
overloading, which was attributed to the volume of urine used (200 j...tl). Therefore, the 
experiment was repeated with three modifications: 1. the units of urease added per 
microlitre of urine was increased to 1; 2. the incubation period was increased to 30 
minutes; and 3. the volume of urine treated with urease was decreased to 50 j...tl. The 
resulting chromatogram (Figure 2) showed that the urea peak, located at RT 16.7 
minutes, did not exhibit excessive overloading. By comparing Figures 1 and 2 it can be 
seen that there are a greater number of peaks in Figure 1. This is due to the greater 
volume of urine used to extract metabolites (i.e. 200 j...tl compared to 50 j...tl). This 
comparison is summarised in Table 1, along with the results of experiments using two 
other extraction volumes (25 j...tl and 10 Ill). 
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Figure 1. GC/MS chromatogram of a 200 Ill urine extract. 0.3 units of urease were 
added per microlitre of urine which was then incubated for 10 minutes. 
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Figure 2. GC/MS chromatogram of a 50 I-ll urine extract. 1 unit of urease was added 
per microlitre of urine and was incubated for 30 minutes. 
3.1.2 Urine volume 
Initial experiments involving catalysed urea hydrolysis saw the need to 
investigate the extraction volume of urine. Table 1 show~ the number of components 
(mean ± SD) and target components (mean ± SD) detected in four different extraction 
volumes of pooled 11-week old male and female Lewis rat urine. It can be seen here 
that there is a significant difference (P<0.05) between each of the volumes tested and 
there is a significant correlation (P<0.01) between the number of components found 
and the urine volume, demonstrating good linearity of the assay method. There is no 
significant difference between the number of target components found for the 
volumes 25 I-ll, 50 I-ll and 200 I-lL At an earlier stage, it was concluded that 200 I-ll of 
urine contributed an overload of material on the GC column (Figure 1), however it also 
yielded the greatest total number of components (Table 1). Extracted urine volumes of 
10, 25 and 50 1-tl showed significantly less components than 200 I-ll (P<0.01), however 
there was much less evidence of overloading with these smaller extraction volumes. A 
50 I-ll extract is shown in Figure 2 with a maximum ion intensity of 3 x 107• Although 
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there was no significant difference between the number of target components 
detected with the 2S and 50 j.tl volumes, it was concluded that SO j.tl was the optimum 
volume to proceed with due to the presence of a significantly higher total number of 
components detected (Table 1). 
Table 1. Number of components (mean ± SD) and target components (mean ± SD) 
detected in 10, 2S, SO and 200 j.tl extraction volumes of urine. 
Urine Volume Samples Number of Components Number of Target 
{j.tl) (n) Components 
10 3 71 ± 4t#¥ so± s 
2S 3 164 ± 2S*#¥ 93 ± 6* 
so 3 230 ± 9*t¥ 108 ± 3* 
200 s S80 ± 26*t# 100 ± 8* 
*significantly different from 10 j.tl (P<O.OS), t significantly different from 2S j.tl (P<O.OS), 
#significantly different from SO j.tl (P<O.OS), ¥significantly different from 200 j.tl 
(P<O.OS). 
3.1.3 Centrifugation 
Some debate has centred on the effect of centrifuging urine prior to 
metabolomic analysis, specifically, the potential loss of metabolites in the sediment of 
the urine during centrifugation [9]. Urine samples (in triplicate) with and without an 
initial centrifugation step (see section 2.2) were prepared for extraction. The number 
of components (mean ± SD) and target components (mean ± SD) that were detected 
are shown in Table 2. Centrifugation resulted in 473 ± 7 components and 44 ± 1 target 
components being detected and the non-centrifuged samples resulted in 436 ± 33 
components and 43 ± 4 components being detected. There was no significant 
difference between the number of components and target components found 
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between the centrifuged and non-centrifuged groups; which show that initial 
centrifugation does not affect the number of metabolites detectable in Lewis and LPK 
rat urine by GC/MS. A et a/. [9] found that metabolites such as myo-inositol, urate, 
hippurate, glycerate, p-hydroxyphenylacetate and a few other unidentified compounds 
were found in greater concentrations in a non-centrifuged group of rat urine. 
However, A et a/. [9] also found that centrifugation improved the response of 
metabolites such as creatinine, phosphorate and allantoin and predicted that this was 
due to improved trimethylsilylation for the lower concentrations of analytes in the 
centrifuged supernatants. Since one of the main aims of this study was to develop a 
method for non-targeted urinary metabolic profiling, it was decided that the 
centrifuged method should be adopted for effective trimethylsilylation, particularly 
because creatinine was to be used as a normalisation technique. 
Table 2. Number of components (Mean ± SD) and target compounds (Mean ± SD) 
detected with and without the initial centrifugation step in the extraction method (n = 
3). 
Treatment Number of Components Number of Target 
Components 
Centrifuged 473 ± 7 44 ± 1 
Non-centrifuged 436 ± 33 43 ±4 
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3.2 Instrumentation 
3.2.1 limit of detection 
Limit of detection is determined by a signal (detector response) that is three 
times the baseline noise. Low detection limits are important for the detection of low 
abundance metabolites in non-targeted metabolomics [11]. Trimethylsilylated D-
mannitol was used to determine the LOD of three different GC/MS systems at two 
sites (Table 3). Seven different concentrations (0.01, 0.05, 0.1, 0.5, 1, 5 and 10 ng.llL-1) 
of D-mannitol were analysed with splitless injections (1 IlL) on each of the instruments 
to obtain the limit of detection. The most sensitive instrument was the ion trap GC/MS 
at Murdoch University (with an LOD of 0.10 ng on column) followed by the quadrupole 
GC/MS at Murdoch University (with an LOD of 0.14 ng on column). These results were 
expected as ion trap mass spectrometers trap all ions and destabilise their trajectories 
in order that they reach the detector in a uniform stream. Linear quadrupole mass 
spectrometers, however, stabilise the ion trajectory for a given m/z species, but this 
can result in the loss of sensitivity for the destabilised ions. An LOD could not be 
obtained for the ion trap GC/MS at ECU due to the apparent absence of D-mannitol. It 
was proposed that D-mannitol was co-eluting with n-nonadecane which resulted from 
the operation of the instrument in constant pressure mode, the only mode available 
due to the age of the instrument. To rectify this problem, the pressure was reduced 
slightly (from 15 to 14 psi) and the temperature ramp was increased in the second 
segment of the run (from 1.0 to 1.1 oc.min-1). This saw a small peak eluting after n-
nonadecane even though the concentration of D-mannitol was 100 ng on column and 
should have been an intense peak in comparison to the alkane. This resulted in the 
exclusion of the GC/MS at ECU due to the inferior sensitivity it exhibited for a 
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compound which is typical of metabolite properties. This finding was supported in 
section 3.2.2. 
Table 3. Comparison of the limit of detection (ng on column) of a quadrupole GC/MS 
system and two ion trap GC/MS/MS systems at two different sites. 
Instrument Institution Limit of Detection 
Quadrupole GC/MS Murdoch 0.14 
lon Trap GC/MS Murdoch 0.10 
lon Trap GC/MS ECU ND 
3.2.2 Detectable components 
As the limit of detection was not particularly different between the quadrupole 
GC/MS and the ion trap GC/MS at Murdoch University, urine samples were prepared 
using the optimised extraction method and run on both instruments as well as the ion 
trap GC/MS at ECU. Surprisingly, the quadrupole GC/MS returned a significantly higher 
(P<O.OS) number of components than the ion trap GC/MS at Murdoch University in 
both the centrifuged and non-centrifuged groups (Table 4). The ion trap GC/MS at ECU 
showed significantly less (P<O.OS) components than both of the GC/MS systems at 
Murdoch, however, these results were expected due to the inferior limit of detection. 
The number of target components was not reported here as the AnalyzerPro user-
generated library was created using the quadrupole GC/MS at Murdoch University 
with D-mannitol retention time lock based retention times. For this reason, library 
matched components would not be returned for either of the ion trap instruments. 
This could not be corrected with retention time locking as Varian instruments do not 
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have this functionality. As a result of these findings, it was decided to proceed with 
urine analysis using the linear quadrupole GC/MS. 
Table 4. Comparison of the number of components (mean± SD) detected in pooled 11 
week old male and female Lewis rats by the quadrupole GC/MS system and two ion 
trap GC/MS/MS systems (n = 3). 
Instrument Number of Components 
Centrifuged Non-centrifuged 
Quadrupole GC/MS (Murdoch) 436±33t# 
lon Trap GC/MS (Murdoch) 160 ± 7*# 152 ± 13*# 
lon Trap GC/MS (ECU) 
*Significantly different from Quadrupole GC/MS (Murdoch), tsignificantly different 
from lon Trap GC/MS/MS (Murdoch), #significantly different from lon Trap GC/MS/MS 
ECU. 
3.2.3 Precision and reproducibility 
A standard curve generated for quantitative analysis is also a useful measure of 
precision for both sample preparation and instrumentation steps. Figure 3 shows the 
peak area of five different concentrations (0.1, 0.5, 1, 5, 10 ng.j..!L-1) of 
trimethylsilylated D-mannitol splitless injections (1 j..!L) on the quadrupole GC/MS at 
Murdoch. The R2 value of 0.9994 indicates a precise and reproducible method and 
system for the concentrations between 0.1 to 10 ng of trimethylsilylated D-mannitol 
on column. D-mannitol was used to obtain LOD, precision and reproducibility data as 
the majority of the high throughput metabolomics work in this laboratory has been 
carried out on fungi, for which D-mannitol was the most abundant compound 
detected. Additionally, D-mannitol has been utilised by Metabolomics Australia to lock 
retention times of instruments across Australia. D-mannitol is cheap, and elutes at 
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approximately half of the total GC/MS analysis time, making it useful for these 
experiments and also for retention time locking. Internal standards are also used as a 
measure of method reproducibility [6, 15]. Figure 4 shows the peak area of 50 ng.J..LL-1 
of the internal standard trimethylsilylated ribitol in each of the injected D-mannitol 
standards. The relative standard deviation (RSD) of the ribitol peak area was 2.68% 
which indicated that the assay (sample preparation and instrumental analysis) was 
highly reproducible. Ribitol was used as an internal standard because it is not present 
in fungi (nor is it present in mammals) and elutes before the 30 minute {sugar 
overload' in fungal samples, and is therefore readily resolved. There are many other 
internal standards that have proven to be stable and reliable such as [2H3]myristic acid 
[15], succinic d4 acid, malonic d2 acid, glycine d5 and glucose 13C6 [6]. However, due to 
the ready availability, the low cost, and the recent success using D-mannitol and ribitol, 
these procedures were continued. 
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Figure 3. Peak area of 0.1, 0.5, 1, 5 and 10 ng.J..LL-1 injections of trimethylsilylated D-
mannitol (RT = 30.6 minutes). 
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Figure 4. Peak area of 50 ng.Jll-1 ribitol in each of the D-mannito l standards (%RSD = 
2.68) . 
3.2.4 Injection mode 
A split injection is commonly used to achieve baseline separation when the 
concentration of a sample is known to be high or i·s unknown. It is a preventative 
measure to minimise overloading. This is especially the case when using capillary 
columns as tens of micrograms of analyte can cause overloading. Although splitless 
injections are widely used in non-targeted urinary metabolic profiling [9, 15, 17, 19], a 
split injection was tested in an attempt to improve signal-to-noise ratio and resolution, 
and to minimise overloading. Whilst the chromatography was improved, the number 
of components detectable was reduced significantly (P<O.OS). Table 5 shows the 
number of components (mean ± SD) and target components detected using splitless 
and split (20:1) injections. The splitless method resulted in the detection of 473 ± 7 
components and 44 ± 1 target component library matches. The 20:1 split method, 
however, resulted in the detection of only 179 ± 7 components and 18 ± 0 target 
component library matches. Due to these findings, subsequent injections were 
performed in splitless mode. 
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Table 5. Number of components (mean ± SD) and target components (mean ± SD) 
detected using splitless and split (20:1) GC methods (n = 3). 
Treatment Number of Components Number of Target Components 
Splitless 473 ± 7 44± 1 
Split (20:1) 179 ± 7* 18 ± O* 
*significantly different from splitless. 
3.3 Data Analysis 
From the 584 ± 44 components detected in the male Lewis rat urine (n = 7) only 
92 ± 5 were library matched (target components) (Table 6). For female LPK rat urine (n 
= 4) 554 ± 31 components were detected of which 96 ± 5 were library matched. 
Analysis of male LPK rat urine resulted in the detection of 587 ± 47 components of 
which 94 ± 5 were library matched. There was no significant difference between the 
number of components and target components found in the two strains and sexes. 
Table 6. Number of components (mean ± SD) and target components found in Lewis 
male and LPK male and female rat urine. 
Strain ··Sex Replicates Number of Components Number of Target Components 
Lewis Male 7 585 ± 44 92 ± 5 
LPK Female 4 554 ± 31 96 ± 5 
LPK Male 6 587 ± 47 94± 5 
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3.3.1 Normalisation 
As mentioned previously, internal standards are a measure of methodology 
reproducibility and can highlight if the signal-to-noise ratio changes between analyses. 
Ribitol was added to each of the urine samples at a desired final concentration of 
15 ng.~L-1 or 15 ng on column. By doing so, each of the peaks in a particular sample 
were normalised to the internal standard to account for any variability in both the 
sample preparation and the instrument. Trimethylsilylated ribitol is a target 
component in the AnalyzerPro user-generated library. In addition to this, the mass 
spectrum of the compound was obtained, as was the deconvoluted mass spectrum, to 
ensure the library match was accurate and to further ensure data was being 
normalised to the correct component. There was a significant correlation {P<0.01) 
between the sum of the peak area of all components in the sample to the respective 
ribitol peak area. Based on this result it was assumed that if ribitol was affected by 
sample preparation and instrument variability, all peaks were subsequently affected 
and normalisation to account for this was therefore warranted. Figure 5 shows the 
peak area of ribitol in each of the urine samples, showing a relative standard deviation 
{RSD) of 14.02%. A desirable RSD is <10%, however, due to the limited volume of 
sample obtained from the rats, this experiment could not be repeated. 
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Figure 5. Peak area of trimethylsilylated ribitol in each of the rat urine samples (%RSD 
= 14.02). Samples are labelled strain (LEW/LPK), sex (M/F) and from A-H for individual 
identification. 
Biofluids such as plasma, serum and cerebrospinal fluid are physiologically 
controlled, however, urine can be particularly varied, mainly due to water 
consumption, but also as a result of other factors [39]. Although food and water were 
available to the animals at all times, it was expected that hydration state would affect 
the concentration of metabolites in the urine and potentially cause significant 
variability in the metabolic profiles, masking any differences that may have been seen 
as a result of disease state. To correct for this, creatinine was identified as a potential 
normalisation strategy. This is common practice in clinical chemistry and metabolomics 
as creatinine is an indicator of the concentration of urine, assuming a constant 
secretion of creatinine into urine [36, 39]. The focus of this study was ARPKD. 
Therefore, there was concern that creatinine levels would be significantly lower in the 
LPK animals than in the Lewis. The result of a one-way ANOVA found that there was no 
significant difference in creatinine attributed to sex and/or strain. This finding was 
supported by Phillips eta/. [35] who found that serum creatinine was not significantly 
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increased in the LPK rat until age 12-weeks. In order to positively identify creatinine in 
the samples, a standard was derivatised and run on the quadrupole GC/MS at 
Murdoch University. The retention time of creatinine was found to be 23.4 minutes 
(Figure 6) and the base peak m/z 115 (Figures 7 and 8). In order to add creatinine to 
the existing AnalyzerPro library, a deconvoluted mass spectrum was obtained (Figure 
8) which excludes interferences such as m/z 73 which is attributed to trimethylsilyl 
groups. The deconvoluted mass spectrum aids in the identification of the correct base 
peak. After the addition of creatinine to the library, the data was re-processed to 
include the identification of creatinine. To ensure that it was correct to assume 
creatinine levels would increase and decrease with changing metabolite concentration, 
the sum of all peak areas in the sample were correlated to the respective creatinine 
peak area. This was found to be significant (P<O.Ol) after ribitol normalisation. 
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Figure 6. GC Chromatogram of trimethylsilyl creatinine (RT 23.4 minutes). 
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Figure 8. Oeconvoluted mass spectrum of trimethylsilyl creatinine. 
3.3.2 Principal component analysis 
Principal component analysis has been employed in metabolomics studies using GC [8, 
9, 15, 17), LC [2, 41-44], MS [11, 22, 39] and 1H NMR [16, 36, 38, 45, 46]. It is a method 
of data transformation that assigns the data a coordinate system whereby in any 
projection of the data (20 or 30), the greatest variance {%) lies on the first coordinate 
(principal component 1). Principal component 2 shows the next greatest variance and 
so on. Figure 9a shows the principal component analysis of male and female 5-week 
old Lewis and LPK rats. This 2-0 projection of data was generated using the log-
transformed raw peak area of target components. At this point, the target components 
had not been normalised to ribitol or creatinine. 18% of the variance between the 
samples was attributed to PC1 and 14% was attributed to PC2. The remaining principal 
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components 3-15 inclusive (not shown) explain $9% of variance. With only 32% of 
variance explained in PCl and PC2 and clear overlapping of the sample groups, this 
model provides little information regarding variability in metabolites as a function of 
disease state. 
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Figure 9a. Principal component analysis of male and female 5-week old Lewis and LPK 
rat urine samples. This output was generated using log-transformed peak area data. 
Figure 9b shows the principal component analysis of male and female 5-week 
old Lewis and LPK rats. This projection of data was generated using the log-
transformed peak area of target components normalised to the internal standard 
ribitol. PC1 explained 28% of the variance between samples and PC2 explained 17% of 
the variance. PC3-15 (not shown) explained ~14% of variance. With an overall 
explained variance of 45% in PC1 and PC2, it was concluded that 13% (i.e. the 
difference in explained variance between Figures 9a and 9b) of variance between 
samples was attributed to the concentration of metabolites in the individual samples 
(i.e. overloading) and not to sample preparation and instrumental analysis. Results 
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reported previously in this section (3.2.3) indicate that the sample preparation and 
instrumental analysis were highly reproducible with a relative standard deviation of 
2.68% for the internal standard ribitol. Section 3.3.1, however, reports the relative 
standard deviation of 14.02% for the internal standard, ribitol. This result (Figure 9b) 
was therefore expected as the signal-to-noise ratio changed between biological 
replicates while the signal-to-noise ratio between technical replicates stayed relatively 
stable. Figure 9b once again shows overlapping of sample groups showing little 
discrimination between diseased and non-diseased animals. 
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Figure 9b. Principal component analysis of male and female 5-week old Lewis and LPK 
rat urine samples. This output was generated using log transformed peak area data 
normalised to the internal standard ribitol. 
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Figure 9c shows the principal component analysis of male and female 5-week 
old Lewis and LPK rats·. This projection of data was generated using the log-
transformed peak area of target components normalised to ribitol and then creatinine. 
40% of the variance between samples is explained by PC1 and 16% by PC2. PC3-15 (not 
shown) each explained ::;; 13%. Therefore, 56% of the total variance was explained by 
the model (PC1 and PC2), of which, 11% was attributed to variation in analyte 
concentration due to the hydration state of the animal. Figures 9a-c shows the 
importance of data transformation and normalisation. These processes minimise the 
impact of variability of high intensity peaks [11] and further illustrate the need for high 
inter-sample reproducibility. Even more so than Figures 9a and 9b, there was a clear 
overlap in sample groups. Having accounted for signal-to-noise variability and 
hydration state, it was expected that this model represented variability attributed to 
individual target components in the samples. Although there is an overlap in sample 
groups, it was seen here that the 5 male animals on the right are the key influence 
attributing to the variance explained by PC1 (40%). Given that 80% of the animals 
influencing PC1 were Lewis males, it was noticed that male diseased and non-diseased 
animals began to show discrimination (Figure 10) after the various normalisation 
techniques. 
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Figure 9c. Principal component analysis of male and female 5-week old Lewis and LPK 
rat urine samples. This output was generated using log transformed peak area data 
normalised to ribitol then creatinine . 
These results (Figures 9a-10) show that PCA is a powerful tool for visualising 
metabolomics data . These models (Figures 9a-c) are representative of approximately 
100 metabolites for 17 individual animals. PCA is commonly used to identify specific 
metabolites which are attributed to variations between disease states [8, 36, 44, 46], 
however, it can also be used as a method for data mining to identify interferences due 
to assay method [15]. In this case, it has been used for both. The X-loadings plot for 
the PCA in Figure 10 (Figure 11) revealed that the metabolites attributing to the 
variance between sample groups were, but were not limited to, D-mannitol, a-
ketoglutarate, uric acid, allantoin and phosphoric acid. The presence of D-mannitol is 
an indication that the chromatographic separations were not sound for the samples 
that attributed to the variance. In particular, the presence of D-mannitol is an 
indication that there was overloading in the samples as higher eukaryotes do not 
synthesise or catabolise D-mannitol [47]. This finding is indicative of a shift in retention 
time due to overloading and resultant misidentification of peaks. It was postulated 
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that the presence of 0-mannitol was the result of the presence of a closely eluting 
sugar with a similar fragmentation pattern. For this reason, 0-mannitol was not 
excluded from the data analysis as it may represent an important sugar which should 
be investigated further in the future. The presence of a-ketoglutarate, uric acid and 
allantoin, however, are indicative that the groups are likely to be separated due to 
disease state. a-ketoglutarate has been linked to hypertension by Akira eta/. [36], and 
hypertension has been identified as a clinical symptom of ARPKO in the LPK rat by 
Phillips eta/. [35] . Further, it is postulated that uric acid and allantoin may be linked to 
renal and/or liver dysgenesis. The reason for the presence of phosphoric acid in the X-
loadings plot remains unknown. It has been postulated that it is an artefact of sample 
preparation. Whilst these findings show a solid foundation for investigating ARPKO 
using metabolomics, food and water intake and urine collection (i.e . spot urine) cannot 
be ruled out as factors influencing variance. Walsh et a/. [40] have identified urinary 
metabolomics as an effective method of determining and assessing dietary intake 
which suggests that food and water should be withheld from the animals to eliminate 
this as a factor attributing to variance. Similarly, Walsh eta/. have identified the need 
to investigate the difference between 24-hour samples and spot samples. Akira eta/. 
[36] were able to explain 76% of variance between young spontaneously hypertensive 
rats and healthy controls using a PCA model after creatinine normalisation. Similarly, 
Vallejo et a/. were able to explain 94% of variance between atherosclerosis patients 
and healthy controls using a PCA model. The total explained variance of the PCA in 
Figure 10 is 68%. This comparatively low explained variance may be attributed to the 
limitations of the study, in particular, food and water intake, and limited sample size. 
In this analysis (figure 10) principal components 3-15 (not shown) explain ~ 15% of 
variance. This suggests that there is further interpretation needed for this data set with 
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respect to principal components beyond PCl and PC2 . In order to do so, all of the 
limitations of the study need to be identified to make accurate and reliable 
interpretations regarding the influence of individual metabolites. 
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Figure 10. Principal component analysis of male 5-week old Lewis and LPK rat urine 
samples. This output was generated using log transformed peak area data normalised 
to ribitol then creatinine. 
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Figure 11. PCA X-loadings plot of male 5-week old Lewis and LPK rat urine samples. 
This output was generated using log transformed peak area data normalised to ribitol 
then creatinine and shows the key metabolites which influence the model described in 
Figure 10. 
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4.1 Conclusion 
CHAPTER FOUR 
CONCLUSION 
There are some interesting findings in the present research, the overall 
outcome of this work being the identification of the need for a well-controlled 
experiment with a greater sample size. With the development of an optimised method 
for non-targeted urinary metabolic profiling of the LPK rat, it is hoped that a 
metabolomics approach may lead to the identification of biomarkers for ARPKD in the 
future. Once the phenotype of the LPK rat model of ARPKD has been thoroughly 
investigated, it is hoped that the findings will contribute to research in human ARPKD. 
The findings of this study, particularly the development of a GC/MS method to analyse 
Lewis and LPK rat urine, demonstrate the potential of (lletabolomics to investigate 
ARPKD. The work in this project has provided preliminary data demonstrating the 
ability to differentiate urine samples on the basis of sex and disease state. Future 
detailed temporal studies are hoped to elucidate key metabolites to identify the onset 
of kidney dysgenesis and aid in determining the function of the ARPKD protein 
fibrocy~tin/polyductin. 
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4.2 Recommendations 
The user generated library at the Metabolomics Australia Node; Murdoch 
University, primarily consists of polar plant metabolites and for further work; 
mammalian metabolites and non-polar metabolites, including lipids, need to be added 
to the library. This can be carried out by complementary analytical techniques such as 
1H NMR to elucidate the structures of the unknown analytes in the samples. These 
results would then be validated with pure standards. Controlled sample collection, 
including food and water prior to sampling, and further optimisation of sample size will 
improve reproducibility of data in the future. Furthermore, the role of creatinine as an 
appropriate urine normalisation technique as a function of kidney dysgenesis needs to 
be investigated. This can be undertaken as a temporal animal based study with 
adequate biological replicates. 
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